284 related articles for article (PubMed ID: 1688340)
1. Dopa decarboxylase activity of the living human brain.
Gjedde A; Reith J; Dyve S; Léger G; Guttman M; Diksic M; Evans A; Kuwabara H
Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2721-5. PubMed ID: 1688340
[TBL] [Abstract][Full Text] [Related]
2. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
[TBL] [Abstract][Full Text] [Related]
3. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.
Deep P; Dagher A; Sadikot A; Gjedde A; Cumming P
Synapse; 1999 Dec; 34(4):313-8. PubMed ID: 10529725
[TBL] [Abstract][Full Text] [Related]
5. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
6. Striatal L-dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis.
Gjedde A; Léger GC; Cumming P; Yasuhara Y; Evans AC; Guttman M; Kuwabara H
J Neurochem; 1993 Oct; 61(4):1538-41. PubMed ID: 8377003
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
[TBL] [Abstract][Full Text] [Related]
8. A within-subject comparison of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa in Parkinson's disease.
Gallagher CL; Christian BT; Holden JE; Dejesus OT; Nickles RJ; Buyan-Dent L; Bendlin BB; Harding SJ; Stone CK; Mueller B; Johnson SC
Mov Disord; 2011 Sep; 26(11):2032-8. PubMed ID: 21638324
[TBL] [Abstract][Full Text] [Related]
9. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion.
de Lonlay P; Simon-Carre A; Ribeiro MJ; Boddaert N; Giurgea I; Laborde K; Bellanné-Chantelot C; Verkarre V; Polak M; Rahier J; Syrota A; Seidenwurm D; Nihoul-Fékété C; Robert JJ; Brunelle F; Jaubert F
J Clin Endocrinol Metab; 2006 Mar; 91(3):933-40. PubMed ID: 16403819
[TBL] [Abstract][Full Text] [Related]
10. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
Hoshi H; Kuwabara H; Léger G; Cumming P; Guttman M; Gjedde A
J Cereb Blood Flow Metab; 1993 Jan; 13(1):57-69. PubMed ID: 8417011
[TBL] [Abstract][Full Text] [Related]
11. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder.
Ernst M; Zametkin AJ; Matochik JA; Pascualvaca D; Jons PH; Cohen RM
Am J Psychiatry; 1999 Aug; 156(8):1209-15. PubMed ID: 10450262
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.
Doudet DJ; Chan GL; Jivan S; DeJesus OT; McGeer EG; English C; Ruth TJ; Holden JE
J Cereb Blood Flow Metab; 1999 Mar; 19(3):278-87. PubMed ID: 10078880
[TBL] [Abstract][Full Text] [Related]
13. (18F) Fluoro-Dopa: a unique gamma emitting substrate for Dopa decarboxylase.
Firnau G; Garnett ES; Sourkes TL; Missala K
Experientia; 1975 Nov; 31(11):1254-5. PubMed ID: 1204761
[No Abstract] [Full Text] [Related]
14. Behavior of fluorinated analogs of L-(3,4-dihydroxyphenyl)alanine and L-threo-(3,4-dihydroxyphenyl)serine as substrates for Dopa decarboxylase.
Borri Voltattorni C; Bertoldi M; Bianconi S; Deng WP; Wong K; Kim I; Herbert B; Kirk KL
Biochem Biophys Res Commun; 2002 Jul; 295(1):107-11. PubMed ID: 12083775
[TBL] [Abstract][Full Text] [Related]
15. [18F]fluoro-L-dopa for the in vivo study of intracerebral dopamine.
Firnau G; Garnett ES; Chirakal R; Sood S; Nahmias C; Schrobilgen G
Int J Rad Appl Instrum A; 1986; 37(8):669-75. PubMed ID: 3021668
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat.
Cumming P; Häusser M; Martin WR; Grierson J; Adam MJ; Ruth TJ; McGeer EG
Biochem Pharmacol; 1988 Jan; 37(2):247-50. PubMed ID: 3124856
[TBL] [Abstract][Full Text] [Related]
17. Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study.
Moore RY; Whone AL; McGowan S; Brooks DJ
Brain Res; 2003 Aug; 982(2):137-45. PubMed ID: 12915249
[TBL] [Abstract][Full Text] [Related]
18. 6-[18F]fluoro-L-dopa uptake and [76Br]bromolisuride binding in the excitotoxically lesioned caudate-putamen of nonhuman primates studied using positron emission tomography.
Hantraye P; Loc'H C; Maziere B; Khalili-Varasteh M; Crouzel C; Fournier D; Yorke JC; Stulzaft O; Riche D; Isacson O
Exp Neurol; 1992 Feb; 115(2):218-27. PubMed ID: 1531196
[TBL] [Abstract][Full Text] [Related]
19. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate.
Firnau G; Sood S; Chirakal R; Nahmias C; Garnett ES
J Neurochem; 1987 Apr; 48(4):1077-82. PubMed ID: 3102690
[TBL] [Abstract][Full Text] [Related]
20. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
